Epidermal Langerhans cell-targeted gene expression by a dectin-2 promoter

Area of Science:

• Immunology
• Molecular Biology
• Genetics

Background:

• Dendritic cells (DCs) and Langerhans cells (LCs) are vital antigen-presenting cells (APCs) for initiating immune responses.
• Targeting LCs for gene-based manipulation has been limited due to the lack of identified LC/DC-specific regulatory elements.
• Dectin-2, a C-type lectin receptor, is selectively expressed by LC-like cell lines and LCs in mouse epidermis.

Purpose of the Study:

• To identify and characterize regulatory elements for LC/DC-specific gene expression.
• To evaluate the potential of the dectin-2 promoter (Dec2FR) for directing gene expression specifically in LCs.
• To establish a foundation for LC-targeted gene expression systems to enhance vaccination and immune regulation.

Main Methods:

• Isolation and characterization of a 3.2-kb nucleotide fragment from the 5'-flanking region of the dectin-2 gene (Dec2FR).
• Utilized a luciferase (Luc) reporter system to assess transcriptional activity of Dec2FR in LC-like XS cells.
• Generated transgenic mice carrying a Dec2FR-regulated Luc gene to evaluate in vivo LC-specific expression.

Main Results:

• The isolated Dec2FR fragment contains regulatory elements (e.g., TATA box, IFN-stimulated response element) driving gene expression specifically in XS cells.
• Dec2FR comprises repressor and enhancer regions that co-regulate XS cell-specific gene expression.
• In transgenic mice, luciferase activity was predominantly found in the skin, exclusively from epidermal LCs, with minimal activity in other APCs and T cells.

Conclusions:

• Epidermal LCs can be selectively targeted for high-level constitutive gene expression using the Dec2FR in vitro and in vivo.
• The dectin-2 promoter (Dec2FR) serves as a powerful tool for LC-specific gene expression.
• This finding provides a basis for developing LC-targeted gene therapy and vaccination strategies.